Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate for injection, cefuroxime tablets/capsules, ampicillin acid, penicillin industrial potassium salt, Touboke Yuekui granules/capsules, remifentanil hydrochloride for injection, sodium cefuroxime for injection, ceftriaxone sodium crude salt, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, 7-ACA, amlodipine besylate tablets, cefoperazone dispersible tablets, and amoxicillin capsules. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Shanghai, China.
Metrics to compare | 600420 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600420PeersSector | |
|---|---|---|---|---|
P/E Ratio | 15.1x | 21.1x | −0.6x | |
PEG Ratio | −1.18 | 0.42 | 0.00 | |
Price/Book | 1.0x | 2.1x | 2.6x | |
Price / LTM Sales | 1.5x | 3.2x | 3.4x | |
Upside (Analyst Target) | - | 27.2% | 41.7% | |
Fair Value Upside | Unlock | 21.3% | 5.0% | Unlock |